FDA Adverse Event Malfunction Summary report: N

1823260-2015-04467

MDR report key: 5210603 · Received November 9, 2015

Report

Report Number
1823260-2015-04467
Event Type
Malfunction
Date Received
November 9, 2015
Date of Event
October 19, 2015
Report Date
November 9, 2015
PMA / PMN Number
K961481
Removal / Correction Number
NA
Product Problem
Yes
Report Source
Manufacturer report
Reporter Location
BR
Reporter Occupation
HEALTH PROFESSIONAL

Narratives

Additional Manufacturer Narrative · 1

THIS EVENT OCCURRED IN (B)(6).

Description of Event or Problem · 1

THE CUSTOMER REPORTED THAT THEY RECEIVED QUESTIONABLE RESULTS FOR A TOTAL OF TWO PATIENT SAMPLES TESTED FOR CARCINOEMBRYONIC ANTIGEN (CEA) AND CARBOHYDRATE ANTIGEN 19-9 (CA 19-9). OF THE TWO SAMPLES, ONE HAD AN ERRONEOUS CEA RESULT THAT WAS REPORTED OUTSIDE OF THE LABORATORY. THE SAMPLE INITIALLY RESULTED AS 8.10 NG/ML ON (B)(6) 2015 AND THIS VALUE WAS REPORTED OUTSIDE OF THE LABORATORY. THE SAMPLE WAS KEPT FROZEN. THE SAMPLE WAS LATER REPEATED ON (B)(6) 2015, RESULTING AS 4.87 NG/ML. THE 4.87 NG/ML VALUE WAS REPORTED OUTSIDE OF THE LABORATORY AND THE PHYSICIAN ASKED THE LABORATORY TO CONFIRM THE RESULT. THE SAMPLE WAS REPEATED ON (B)(6) 2015, RESULTING AS 8.22 NG/ML. BOTH THE 8.10 NG/ML AND 8.22 NG/ML VALUES WERE CONSIDERED TO BE CORRECT. THE PATIENT WAS NOT ADVERSELY AFFECTED. CEA REAGENT LOT NUMBER 180517 WAS USED FOR THE FIRST AND SECOND MEASUREMENTS OF THE SAMPLE. THE EXPIRATION DATE FOR THIS REAGENT WAS ASKED FOR, BUT NOT PROVIDED. CEA REAGENT LOT NUMBER 185797 WAS USED FOR THE THIRD MEASUREMENT OF THE SAMPLE. THE EXPIRATION DATE FOR THIS REAGENT WAS ASKED FOR, BUT NOT PROVIDED. THE FIELD SERVICE ENGINEER NOTICED THE PRESENCE OF FIBRIN IN THE PATIENT SAMPLE. A SPECIFIC ROOT CAUSE COULD NOT BE DETERMINED BASED ON THE PROVIDED INFORMATION. THE PROVIDED CALIBRATION AND CONTROL DATA DO NOT REVEAL ANY GENERAL ISSUE WITH THE PRODUCTS USED AS RESULTS ARE WITHIN SPECIFICATIONS. THE FIELD SERVICE ENGINEER FOUND FIBRIN IN THE SAMPLE. THE MOST LIKELY ROOT CAUSE OF THE INCORRECT RESULT IS FIBRIN IN THE SAMPLE.

Patients

Seq Age Sex Outcome Treatment
1 050 YR LEVOTIROXINA